Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Other Operating Expenses (2017 - 2022)

Lexaria Bioscience's Other Operating Expenses history spans 7 years, with the latest figure at $77775.0 for Q2 2023.

  • For Q2 2023, Other Operating Expenses changed N/A year-over-year to $77775.0; the TTM value through Feb 2024 reached $77775.0, down 94.89%, while the annual FY2022 figure was $1.5 million, 0.0% changed from the prior year.
  • Other Operating Expenses for Q2 2023 was $77775.0 at Lexaria Bioscience, down from $1.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.5 million in Q1 2021 and bottomed at -$844360.0 in Q4 2020.
  • The 5-year median for Other Operating Expenses is $996163.5 (2019), against an average of $780593.1.
  • The largest YoY upside for Other Operating Expenses was 47.79% in 2020 against a maximum downside of 209.72% in 2020.
  • A 5-year view of Other Operating Expenses shows it stood at $769583.0 in 2019, then plummeted by 209.72% to -$844360.0 in 2020, then soared by 280.34% to $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then tumbled by 94.89% to $77775.0 in 2023.
  • Per Business Quant, the three most recent readings for LEXX's Other Operating Expenses are $77775.0 (Q2 2023), $1.5 million (Q3 2022), and $1.5 million (Q1 2021).